Close Menu

NEW YORK ─ Ortho Clinical Diagnostics said after the market close on Wednesday that it has priced an initial public offering of 76,000,000 ordinary shares at $17 per share for anticipated gross proceeds of $1.29 billion.

Shares of the Raritan, New Jersey-based pure-play diagnostics firm are expected to begin trading Thursday on the Nasdaq under the symbol OCDX.

Ortho has granted the IPO underwriters a 30-day option to purchase up to 11,400,000 additional shares at the initial public offering price less underwriting discounts and commissions.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.